Physician profile
Lawrence J Witmer
NPI 1639130768
$10,705.80
in general payments reported to CMS, 2019-2025
26 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $185 · 2021: $247 · 2022: $3,391 · 2023: $1,864 · 2024: $2,135 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,006 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,006.21 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,115.02 | 2019-2025 | Watchman Access System, Versacross Access Solution, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $1,060.98 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $963.73 | 2019-2025 | |
| Lilly USA, LLC | $648.65 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $644.16 | 2022-2025 | Qulipta, Ubrelvy, Synthroid |
| Exact Sciences Corporation | $431.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $329.19 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $323.50 | 2023-2025 | Veozah, Myrbetriq |
| Atricure, INC. | $304.36 | 2023-2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.21 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.97 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $257.58 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $168.75 | 2022 | |
| Horizon Therapeutics Plc | $141.43 | 2023 | Krystexxa |
| Novo Nordisk INC | $127.00 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $120.40 | 2019 | |
| Amgen INC. | $114.11 | 2019-2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $93.68 | 2024-2025 | Voquezna |
| Lundbeck LLC | $79.01 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $60.11 | 2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $35.72 | 2019-2023 | |
| Ibsa Pharma INC. | $33.87 | 2022 | |
| Axsome Therapeutics, INC. | $26.22 | 2025 | Auvelity |
| Allergan, INC. | $23.02 | 2019 | |
| Shire North American Group INC | $16.24 | 2019 | |
| Tanabe Pharma America, INC. | $14.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Witmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.